Colucci WS. Alpha-adrenergic receptor blockade with prazosin . Ann Intern Med . 1982;;97:67-77.
Frishman WH, Charlap S. α-Adrenergic blockers . Med Clin North Am . 1988;;72:427-440.
Cubeddu LX. New alpha1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance . Am Heart J . 1988;;116:133-162.
Grimm RH Jr. α1-Antagonists in the treatment of hypertension . Hypertension . 1989;;13(
(suppl I)
):I-131-I-136.
Schäfers RF, Reid JL. Alpha blockers . In: Kaplan NM, Brenner BM, Laragh JH, eds. New Therapeutic Strategies in Hypertension . New York, NY: Raven Press, Ltd; 1989;:51-69.
1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure . Arch Intern Med . 1988;;148:1023-1038.
Ramsay LE, Parnell L, Waller PC. Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker . Postgrad Med J . 1987;;63:99-103.
Tomada F, Takata M, Yoshida K, Yasumoto K, Mikawa M, Sasayama S. Hemodynamic and endocrinological effects of a new selective α1-blocking agent, terazosin, in patients with essential hypertension: results of long-term treatment . Am J Hypertens . 1989;;2:834-839.
Ames RP, Chrysant SG, Gonzalez F, Schnaper HW, Spann S, Velasquez MT. Effectiveness of doxazosin in systemic hypertension . Am J Cardiol . 1989;;64:203-208.
Alpha-blockade for hypertension: indifferent past, uncertain future . Lancet . 1989;;1:1055-1056. Editorial.
Julius S. Are different hemodynamic patterns of antihypertensive drugs clinically important? Eur J Clin Pharmacol . 1990;;38:S125-S128.
Kaplan NM. Clinical Hypertension . 5th ed. Baltimore, Md: Williams & Wilkins; 1990;.
Thompson PD, Cullinane EM, Nugent AM, Sady MA, Sady SP. Effect of atenolol or prazosin on maximal exercise performance in hypertensive joggers . Am J Med . 1989;;86(
(suppl 1B)
):104-109.
Michel MC, Brodde O-E, Insel PA. Peripheral adrenergic receptors in hypertension . Hypertension . 1990;;16:107-120.
Meredith PA, Elliott HL, Kelman AW, Reid JL. Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline α-adrenoceptor agonists in normotensive volunteers . J Cardiovasc Pharmacol . 1985;;7:532-537.
Weber MA, Tonkon MJ, Klein RC. Effect of antihypertensive therapy on the circadian blood pressure pattern . Am J Med . 1987;;82(
(suppl 1A)
):50-52.
Deter G, Cutler RE, Dietz AJ, Lewin AJ, Vlachakis N. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension . Am J Med . 1986;;80(
(suppl 5B)
):62-67.
Smyth P, Pringle S, Jackson G, Lorimer AR. 24-Hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo . Eur J Clin Pharmacol . 1988;;34:613-618.
Stanaszek WF, Kellerman D, Brogden RN, Romankiewicz JA. Prazosin update: a review of its pharmacological properties and therapeutic use in hypertension . Drugs . 1983;;25:339-384.
Humphreys JE, Waite MA. Alpha-1 blockers: a new generation of antihypertensive agents . J Clin Pharm Ther . 1989;;14:263-283.
Mroczek WJ, Fotiu S, Davidov ME, Finnerty FA Jr. Prazosin in hypertension: a double-blind evaluation with methyldopa and placebo . Curr Ther Res . 1974;;16:769-777.
Mulvihill-Wilson J, Graham RM, Pettinger W, et al. Comparative effects of prazosin and phenoxybenzamine on arterial blood pressure, heart rate, and plasma catecholamines in essential hypertension . J Cardiovasc Pharmacol . 1979;;1(
(suppl)
):S1-S7.
McNair A, Rasmussen S, Nielsen PE, Rasmussen K. The antihypertensive effect of prazosin on mild to moderate hypertension, changes in plasma volume, extracellular volume and glomerular filtration rate . Acta Med Scand . 1980;;207:413-416.
Torvik D, Madsbu H-P. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension . Br J Clin Pharmacol . 1986;;21:69S-75S.
Batey DM, Nicolich MJ, Lasser VI, Jeffrey SS, Lasser LN. Prazosin versus hydrochlorothiazide as initial antihypertensive therapy in black versus white patients . Am J Med . 1989;;86(
(suppl 1B)
):74-78.
Stokes GS, Weber MA. Prazosin: preliminary report and comparative studies with other antihypertensive agents . BMJ . 1974;;2:298-300.
Larochelle P, Du Souich P, Hamet P, Larocque P, Armstrong J. Prazosin plasma concentrations and blood pressure reduction . Hypertension . 1982;;4:93-101.
Izzo JL Jr, Horwitz D, Keiser HR. Physiologic mechanisms opposing the hemodynamic effects of prazosin . Clin Pharmacol Ther . 1981;;19:7-11.
Webb DJ, Fulton JD, Leckie BJ, et al. The effect of chronic prazosin therapy on the response of the renin-angiotensin system in patients with essential hypertension . J Hum Hypertens . 1987;;1:195-200.
Nicholson JP, Resnik LM, Pickering TG, Marion R, Sullivan P, Laragh JH. Relationship of blood pressure response and the renin-angiotensin system to first-dose prazosin . Am J Med . 1985;;78:241-244.
Koshy MC, Mickley D, Bourgoignie J, Blaufox MD. Physiologic evaluation of a new antihypertensive agent: prazosin HCl . Circulation . 1977;;55:533-537.
Bauer JH, Jones LB, Gaddy P. Effects of prazosin therapy on BP, renal function, and body fluid composition . Arch Intern Med . 1984;;144:1196-1200.
New Zealand Hypertension Study Group: Four- to seven-year follow-up of patients on prazosin . N Z Med J . 1980;;92:341-342.
Walker RG, Whitworth JA, Saines D, Kincaid-Smith P. Long-term treatment of moderate and severe hypertension and lack of 'tolerance.' Med J Aust . 1981;;2:146-147.
Dauer AD. Terazosin: an effective once-daily monotherapy for the treatment of hypertension . Am J Med . 1986;;80(
(suppl 5B)
):29-34.
Luther RR, Klepper MJ, Maurath CJ, Glassman HN, Achari R, Laddu AT. Efficacy of terazosin in the treatment of essential hypertension in blacks . J Hum Hypertens . 1990;;4:151-153.
Cox DA, Leader JP, Milson JA, Singleton W. The antihypertensive effects of doxazosin: a clinical overview . Br J Clin Pharmacol . 1986;;21:83S-90S.
Scott PJW, Hosie J, Scott MGB. A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients . Eur J Clin Pharmacol . 1988;;34:119-123.
Ames RP, Kiyasu JY. Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins . J Clin Pharmacol . 1989;;29:123-127.
Talseth T, Westlie L, Daae L. A long-term study of atenolol and doxazosin in mild and moderate hypertension . J Hum Hypertens . 1990;;4(
(suppl 3)
):39-44.
Hayduk K, Schneider HT. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin . Am J Cardiol . 1987;;59(
(suppl)
):95G-98G.
Stokes GS, Graham RM, Gain JM, Davis PR. Influence of dosage and dietary sodium on the first-dose effects of prazosin . BMJ . 1977;;1:1507-1508.
Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins . Arch Intern Med . 1988;;148:1280-1288.
Luther RR, Glassman HN, Estep CB, Maurath CJ, Jordan DC. The effects of terazosin and methyclothiazide on blood pressure and serum lipids . Am Heart J . 1989;;117:842-847.
Cubeddu LX, Pool JL, Bloomfield R, et al. Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension . Am J Hypertens . 1988;;1:158-167.
Leren TP. Doxazosin increases low density lipoprotein receptor activity . Acta Pharmacol Toxicol . 1985;;56:269-272.
Rubba P, De Simone B, Marotta T, Leccia G, Soro S, Ferrara LA. Adrenergic blocking agents and lipoprotein lipase activity . J Endocrinol Invest . 1989;;12:119-122.
Sheu WH-H, Swislocki ALM, Hoffman BB, Reaven GM, Chen Y-DI. Effect of prazosin treatment on HDL kinetics in patients with hypertension . Am J Hypertens . 1990;;3:762-768.
Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension . Diabetologia . 1988;;31:415-420.
Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension . N Engl J Med . 1989;;321:868-873.
Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups . J Hypertens . 1989;;7:551-559.
Shionoiri H, Noda K, Miyamoto K, et al. Glucose tolerance during chronic prazosin therapy in patients with essential hypertension . Curr Ther Res . 1986;;40:171-180.
Scheen AJ, Castillo M, Salvatore T, Lefebvre PJ. Lack of deleterious effects of the alpha1-adrenoceptor blocking agent doxazosin on insulin secretion and insulin sensitivity in healthy men . Curr Ther Res . 1989;;46:200-206.
Feher MD, Henderson AD, Wadsworth J, et al. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension; results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects . J Hum Hypertens . 1990;;4:571-577.
Anderton JL, Notghi A. An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency . J Hum Hypertens . 1990;;4(
(suppl 3)
):52-57.
Ram CVS, Gonzalez D, Kulkarni P, et al. Regression of left ventricular hypertrophy in hypertension: effects of prazosin therapy . Am J Med . 1989;;86(
(suppl 1B)
):66-69.
Yasumoto K, Takata M, Yoshida K, Mikawa M, Tomoda F, Sasayama S. Reversal of left ventricular hypertrophy by terazosin in hypertensive patients . J Hum Hypertens . 1990;;4:13-18.
Corral JC, López NC, Pecorelli A, Rincón LA, Terán YD. Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study . Am Heart J . 1991;;121(
(suppl 1)
):352-356.
Hedlund H, Andersson K-E, Ek A. Effects of prazosin in patients with benign prostatic obstruction . J Urol . 1983;;130:275-278.
Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flannigan M, Milroy EJG. Prazosin in the treatment of prostatic obstruction . Br J Urol . 1987;;60:136-142.
Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension: a review . Hypertension . 1989;;13(
(suppl I)
):I-36-I-44.